In This Section

ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Look, How Far We've Come!

Sunday April 07, 2019

8:00 am - 10:00 am Eastern Time (ET)

Room W206 A


Chair :

Yagna Jarajapu
North Dakota State University

Rita Valentino
National Institute on Drug Abuse

The alternative axis of renin angiotensin system, ACE2/Angiotensin-(1-7)/Mas receptor, has attracted massive interest among academia and industry. Originally seen as counterbalancing the ACE/Ang II axis in cardiovascular system, increased understanding of the biologic effects of Angiotensin-(1-7) has shown that this pathway is relevant for diseases of other organ systems including hematologic, neurologic, vascular, musculoskeletal and metabolic disorders. Advancements range from it’s interaction with gut-microbiome and non-addictive analgesia to stimulation of endothelial cells and their progenitors for the treatment of ischemic disorders. This symposium will update the ASPET community with the recent advancements and discuss novel hypotheses and pharmacotherapeutic opportunities.


Robson Santos - Federal University of Minas Gerais

Neuropharmacology of Angiotensin-(1-7)/Mas Receptor Pathway

Robin Shoemaker - University of Kentucky

ACE2 and Sex-Differences in Obesity-Induced Hypertension

Mohan Raizada - University of Florida College of Medicine

ACE2 in the Gut-Brain Axis in Cardiopulmonary Diseases

Todd Vanderah - University of Arizona

Angiotensin-(1-7)/Mas Receptor Pathway: A Novel Non-Addictive Analgesic Target

Richard Franklin - Constant Pharmaceuticals

Angiotensin-(1-7): Mechanism to Medicine

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019